{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T01:29:18Z","timestamp":1786325358679,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.intimp.2026.117053","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T03:35:47Z","timestamp":1782358547000},"page":"117053","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Repurposing AZD-7762 as a novel direct NLRP3 inhibitor for the treatment of inflammatory diseases"],"prefix":"10.1016","volume":"186","author":[{"given":"Lu","family":"Zong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinguo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.intimp.2026.117053_bb0005","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/cmi.2015.95","article-title":"Molecular mechanisms regulating NLRP3 inflammasome activation","volume":"13","author":"Jo","year":"2016","journal-title":"Cell. Mol. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2026.117053_bb0010","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202006194","article-title":"The NLRP3-inflammasome as a sensor of organelle dysfunction","volume":"219","author":"Seoane","year":"2020","journal-title":"J. Cell Biol."},{"issue":"10","key":"10.1016\/j.intimp.2026.117053_bb0015","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/ni.3538","article-title":"NLRP3 inflammasome inhibition is disrupted in a group of auto-inflammatory disease CAPS mutations","volume":"17","author":"Mortimer","year":"2016","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2026.117053_bb0020","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.4049\/jimmunol.1601745","article-title":"Deletion of Nlrp3 augments survival during polymicrobial sepsis by decreasing autophagy and enhancing phagocytosis","volume":"198","author":"Jin","year":"2017","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2026.117053_bb0025","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1136\/gut.2009.197822","article-title":"Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome","volume":"59","author":"Bauer","year":"2010","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.intimp.2026.117053_bb0030","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/ni.1935","article-title":"Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes","volume":"11","author":"Masters","year":"2010","journal-title":"Nat. Immunol."},{"issue":"7293","key":"10.1016\/j.intimp.2026.117053_bb0035","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"issue":"7434","key":"10.1016\/j.intimp.2026.117053_bb0040","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nature11729","article-title":"NLRP3 is activated in Alzheimer\u2019s disease and contributes to pathology in APP\/PS1 mice","volume":"493","author":"Heneka","year":"2013","journal-title":"Nature"},{"issue":"1\u20132","key":"10.1016\/j.intimp.2026.117053_bb0045","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cell.2014.11.047","article-title":"Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome","volume":"160","author":"Yan","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2026.117053_bb0050","article-title":"The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors","volume":"13","author":"Zhan","year":"2022","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2026.117053_bb0055","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1021\/acschembio.1c00218","article-title":"A probe for NLRP3 inflammasome inhibitor MCC950 identifies carbonic anhydrase 2 as a novel target","volume":"16","author":"Kennedy","year":"2021","journal-title":"ACS Chem. Biol."},{"issue":"3","key":"10.1016\/j.intimp.2026.117053_bb0060","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.intimp.2026.117053_bb0065","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1158\/1535-7163.MCT-08-0492","article-title":"AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies","volume":"7","author":"Zabludoff","year":"2008","journal-title":"Mol. Cancer Ther."},{"issue":"12","key":"10.1016\/j.intimp.2026.117053_bb0070","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1158\/0008-5472.CAN-09-3573","article-title":"Mechanism of radiosensitization by the Chk1\/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair","volume":"70","author":"Morgan","year":"2010","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.intimp.2026.117053_bb0075","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41423-025-01275-w","article-title":"NLRP3 inflammasome in neuroinflammation and central nervous system diseases","volume":"22","author":"Xu","year":"2025","journal-title":"Cell. Mol. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2026.117053_bb0080","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.cell.2014.02.008","article-title":"Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes","volume":"156","author":"Lu","year":"2014","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.intimp.2026.117053_bb0085","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.immuni.2013.05.016","article-title":"K(+) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter","volume":"38","author":"Munoz-Planillo","year":"2013","journal-title":"Immunity"},{"issue":"7329","key":"10.1016\/j.intimp.2026.117053_bb0090","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nature09663","article-title":"A role for mitochondria in NLRP3 inflammasome activation","volume":"469","author":"Zhou","year":"2011","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.intimp.2026.117053_bb0095","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.immuni.2016.08.010","article-title":"K(+) efflux-independent NLRP3 inflammasome activation by small molecules targeting mitochondria","volume":"45","author":"Gross","year":"2016","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.intimp.2026.117053_bb0100","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nri.2016.58","article-title":"Inflammasomes: mechanism of assembly, regulation and signalling","volume":"16","author":"Broz","year":"2016","journal-title":"Nat. Rev. Immunol."},{"issue":"7590","key":"10.1016\/j.intimp.2026.117053_bb0105","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/nature16959","article-title":"NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux","volume":"530","author":"He","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.intimp.2026.117053_bb0110","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41419-025-07578-0","article-title":"A small molecule directly targets NLRP3 to promote inflammasome activation and antitumor immunity","volume":"16","author":"Liu","year":"2025","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.intimp.2026.117053_bb0115","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010013","article-title":"Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors","volume":"13","author":"Nelson","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"19","key":"10.1016\/j.intimp.2026.117053_bb0120","doi-asserted-by":"crossref","first-page":"8041","DOI":"10.1073\/pnas.0611496104","article-title":"Cryopyrin\/NALP3 binds ATP\/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling","volume":"104","author":"Duncan","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.intimp.2026.117053_bb0125","doi-asserted-by":"crossref","first-page":"334","DOI":"10.4049\/jimmunol.1202737","article-title":"TLR agonists stimulate Nlrp3-dependent IL-1beta production independently of the purinergic P2X7 receptor in dendritic cells and in vivo","volume":"190","author":"He","year":"2013","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2026.117053_bb0130","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.tips.2025.04.007","article-title":"Targeting the NLRP3 inflammasome for inflammatory disease therapy","volume":"46","author":"Cabral","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"issue":"11","key":"10.1016\/j.intimp.2026.117053_bb0135","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1084\/jem.20171419","article-title":"Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders","volume":"214","author":"Jiang","year":"2017","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.117053_bb0140","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1038\/s41467-018-04947-6","article-title":"Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity","volume":"9","author":"He","year":"2018","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.intimp.2026.117053_bb0145","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41423-021-00683-y","article-title":"RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor","volume":"18","author":"Chen","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2026.117053_bb0150","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41589-019-0277-7","article-title":"MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition","volume":"15","author":"Coll","year":"2019","journal-title":"Nat. Chem. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117053_bb0155","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10528-024-10687-8","article-title":"Comprehensive analyses of PANoptosome with potential implications in cancer prognosis and immunotherapy","volume":"63","author":"Cai","year":"2025","journal-title":"Biochem. Genet."},{"issue":"4","key":"10.1016\/j.intimp.2026.117053_bb0160","doi-asserted-by":"crossref","DOI":"10.1063\/5.0126095","article-title":"Glutathione-sensitive nanoparticles enhance the combined therapeutic effect of checkpoint kinase 1 inhibitor and cisplatin in prostate cancer","volume":"6","author":"Peng","year":"2022","journal-title":"APL Bioeng."},{"issue":"1","key":"10.1016\/j.intimp.2026.117053_bb0165","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/s41467-018-03760-5","article-title":"Small molecules promote CRISPR-Cpf1-mediated genome editing in human pluripotent stem cells","volume":"9","author":"Ma","year":"2018","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.intimp.2026.117053_bb0170","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41589-023-01466-4","article-title":"Checkpoint kinase 2 controls insulin secretion and glucose homeostasis","volume":"20","author":"Chong","year":"2024","journal-title":"Nat. Chem. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117053_bb0175","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00018-024-05340-x","article-title":"Identification of novel neuroprotectants against vincristine-induced neurotoxicity in iPSC-derived neurons","volume":"81","author":"Petrova","year":"2024","journal-title":"Cell. Mol. Life Sci."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926008994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926008994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:54:39Z","timestamp":1786323279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926008994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":35,"alternative-id":["S1567576926008994"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117053","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing AZD-7762 as a novel direct NLRP3 inhibitor for the treatment of inflammatory diseases","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117053"}}